Global cholera vaccines market is anticipated to grow significantly with a CAGR of 10% during forecast period due to rising government initiatives in immunization program and growing incidence of cholera particularly in developing countries in Asia and Africa would drive the growth of cholera vaccines market globally.
Cholera is an infection of the small intestine by strains of the bacterium Vibrio cholera, which can cause death of the patient if left untreated. According to the World Health Organization (WHO) every year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide; it is affected primarily in Africa, South and Southeast Asia, and South Americas. Some factors such as higher prevalence of cholera in some African and south Asian countries and government initiative in immunization program are prime factors that driving the growth of cholera vaccines market globally. For the purpose of study market is segmented on the basis of product type such as dukoral, shanchol, vaxchora and others vaccines and geography. It is studied that, there are three WHO-prequalified, killed, whole-cell oral cholera vaccines are currently extensively use in market; among these Dukoral was observed as largest revenue contributing segment because it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries and it prevent diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC) are primarily driving the growth of Dukoral market globally.
For the purpose of this study, the global cholera vaccines market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country level markets that majorly determine the regional industry trends. Among the considered regional markets, Asia Pacific currently dominates the global cholera vaccines market because large number of affected populations in South-East Asian countries and government initiatives in immunization program are prime factors that driving the market growth in Asia Pacific. However, it is estimated that North America will show the highest growth during forecast period and growth will mainly fuel by a new approved oral vaccine Vaxchora, as it is the only vaccine available in the United States for protection against cholera.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cholera vaccines market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global cholera vaccines market. This report concludes with company profiles section that highlights major information about the key players engaged in global cholera vaccines market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.
It is studied that in the base year 2021, Dukoral held largest market share, due to some factors such as it is the only approved cholera vaccine available for European, Canadian and Australian travelers, it prevents diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC), it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries are primarily driving the growth of Dukoral market. On the other hand Vaxchora will expected to show significant growth during forecast period due to government recommendation for use in adults 18 through 64 years of age traveling to cholera-affected areas, it is the only vaccine available in the United States for protection against cholera and the only single dose vaccine for cholera currently licensed anywhere in the world these factors would expected to drive the market during forecast period.
Asia Pacific Dominates the market
In the base 2021, Asia Pacific was observed as the largest market for cholera vaccines because large pool of patients suffering with cholera, increasing healthcare awareness, government initiatives in treatment and awareness program are primarily driving the market growth in Asia Pacific. On the other hand North America expected to show fastest growth during forecast period because Vaxchora is the only vaccine available in the United States for protection against cholera and recommended use in adults 18 through 64 years of age traveling to cholera-affected areas would expected to assist the market growth in North America.
According to World Health Organization (WHO), cholera represents an estimated burden of 1.4 to 4.0 million cases, and 21,000 to 143,000 deaths per year worldwide. For the purpose of this study, the global cholera market is regionally categorized as North America, Europe, Asia Pacific, LATAM and MEA; among the considered regional markets North America is expected to dominate the cholera market during forecast period due to higher healthcare awareness among general population, government initiatives in treatment and awareness program, higher cost of vaccines and presence of key manufacturer would drive the market growth in North America, recently approved vaxchora would primarily assist market growth in North America. Centers for Disease Control and Prevention (CDC) recommendation for travelers to cholera-affected regions would fuel the market growth in United States. On the other hand, Asia Pacific is currently dominating the Cholera vaccines market due to increasing awareness of immunization, higher number of targeted population and government initiatives in awareness program are primarily driving the market growth in Asia Pacific.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cholera Vaccines market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Product
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
